Pharmaceutical Stocks are Gaining Momentum: The Defensive Winners of 2025
Reading Time: 2 minutes
In times of increased market volatility, pharmaceutical stocks are experiencing a remarkable comeback. While tech stocks are under pressure, investors are increasingly seeking refuge in defensive sectors with stable cash flows and moderate growth potential. Five companies stand out in particular: Gilead Sciences benefits from its HIV blockbuster Biktarvy and is on the verge of launching an annually administered HIV prevention medication. The stock shows strong technical signals and could soon reach new heights. Amgen is recovering despite...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
